Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
17th February 2021 | Peter A. Thompson | 1,285,714 | Open or private purchase | $3.50 | $4,499,999.00 |
12th February 2021 | Carl L Gordon | 104,050 | Grant/award etc. | $13.00 | $1,352,650.00 |
12th February 2021 | Advisors Llc Orbimed | 104,050 | Grant/award etc. | $13.00 | $1,352,650.00 |
12th February 2021 | Advisors Llc Orbimed | 420,299 | Grant/award etc. | $13.00 | $5,463,887.00 |
12th February 2021 | Carl L Gordon | 420,299 | Grant/award etc. | $13.00 | $5,463,887.00 |
9th February 2021 | Advisors Llc Orbimed | 190,000 | Open or private purchase | $17.00 | $3,230,000.00 |
9th February 2021 | Advisors Llc Orbimed | 285,000 | Open or private purchase | $17.00 | $4,845,000.00 |
9th February 2021 | Carl L Gordon | 1,989,723 | Conversion of derivative | $0.00 | |
9th February 2021 | Carl L Gordon | 1,326,481 | Conversion of derivative | $0.00 | |
9th February 2021 | Carl L Gordon | 285,000 | Open or private purchase | $17.00 | $4,845,000.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.
25th February 2021
11th January 2021